Subscribe To
SWTX / SpringWorks Therapeutics Shares Jump On HC Wainwright Bullish Pitch
SWTX News
By Seeking Alpha
July 12, 2023
SpringWorks Therapeutics: FDA Decision Date Ahead
Today we revisit SpringWorks Therapeutics, Inc. for the first time in nearly a year. The company's primary drug asset is on the cusp of garnering Spri more_horizontal
By Reuters
June 5, 2023
US FDA delays decision on SpringWorks Therapeutics' tumor treatment
The U.S. Food and Drug Administration (FDA) has extended its decision for SpringWorks Therapeutics Inc's tumor treatment by three months as the health more_horizontal
By Seeking Alpha
April 14, 2023
SpringWorks Therapeutics: Pfizer Offshoot With Interesting Pipeline
SpringWorks Therapeutics: Pfizer Offshoot With Interesting Pipeline more_horizontal
By Benzinga
June 13, 2022
SpringWorks Therapeutics Shares Jump On HC Wainwright Bullish Pitch
HC Wainwright points out that investors are enthusiastic about SpringWorks Therapeutics Inc (NASDAQ: SWTX) nirogacestat clinical profile for desmoi more_horizontal
By GlobeNewsWire
June 10, 2022
SpringWorks Therapeutics to Present Progress Across the Company's Targeted Oncology Portfolio at Virtual R&D Day
-- NDA filing for Nirogacestat in Desmoid Tumors, Which Will Be Reviewed Under the FDA's Real-Time Oncology Review (RTOR) Program, Expected in Second more_horizontal
By Invezz
May 27, 2022
Here is why SpringWorks Therapeutics jumped 20%
SpringWorks Therapeutics Inc. (NASDAQ: SWTX) stock jumped 20% after the clinical-stage company focusing on life-changing treatment for cancer, and rar more_horizontal
By Zacks Investment Research
May 25, 2022
SpringWorks (SWTX) Down Despite Desmoid Tumors Study Meeting Goal
SpringWorks' (SWTX) phase III study evaluating its investigational candidate, nirogacestat, in adult patients with progressing desmoid tumors, meets p more_horizontal
By Seeking Alpha
May 2, 2022
SpringWorks Therapeutics: Rating Buy Ahead Of Mid-Year Data Releases
Data from Phase 3 trial for Nirogacestat in treating desmoid tumors and Phase 2 combination trial with anti-BCMA antibody Blenrep in relapsed/refracto more_horizontal